BET Protein Inhibition for Pulmonary Arterial Hypertension

PHA Canada
Mar 14, 2022
1 min read

Updated: Nov 7, 2024

This pilot study added apabetalone to people's PAH therapy twice daily for 16 weeks to see if a future clinical trial evaluating bromodomain inhibition in pulmonary arterial hypertension might be feasible. They also aimed to provide preliminary evidence that apabetalone may be safe and effective in PAH.

Read the original journal article

Recent Posts

Promising results for drug candidate CS1

This press release reports that over the 12 months of their Expanded Access Program enrolling ten patients, the majority of patients with pulmonary arterial hypertension who completed treatment with d

Using sotatercept off-label in children

Clinical trials for sotatercept didn't include children, so any pediatric use is off-label. This study, conducted at one children's hospital in San Diego, evaluated sotatercept in 7 pediatric patients

Phase 1 trial of treprostinil prodrug patch succeeds

A 9-participant phase 1 clinical trial used a patch to deliver a prodrug of treprostinil (a prodrug is something that is metabolized into the drug in question inside the body). Each participant wore a

Comments